Cargando…

AB122. MicroRNA-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence

Castration-resistant prostate cancer (CRPC) and its treatment are challenging issues in prostate cancer management. Here, we report that miR-663 is upregulated in CRPC tissues. Overexpression of miR-663 in prostate LNCaP cells promotes cell proliferation and invasion, neuroendocrine differentiation,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chuanliang, Jiao, Li, Deng, Zhen, Yu, Yongwei, Li, Yun, Yang, Chun, Chen, Junyi, Liu, Zhiyong, Huang, Gang, Li, Longcheng, Sun, Yinghao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708392/
http://dx.doi.org/10.3978/j.issn.2223-4683.2014.s122
Descripción
Sumario:Castration-resistant prostate cancer (CRPC) and its treatment are challenging issues in prostate cancer management. Here, we report that miR-663 is upregulated in CRPC tissues. Overexpression of miR-663 in prostate LNCaP cells promotes cell proliferation and invasion, neuroendocrine differentiation, and reduction in dihydrotestosterone-induced upregulation of prostate-specific antigen expression. Furthermore, results of in situ hybridization show that miR-663 expression is correlated with Gleason score and TNM stage and is an independent prognostic predictor of clinical recurrence. Together, these findings suggest that miR-663 is a potential oncomiR for CRPC and may serve as a tumor biomarker for the early diagnosis of CRPC.